tumor cell biology program - Sylvester Comprehensive Cancer Center

More documents

Recommendations

Info

20 UM/Sylvester Comprehensive Cancer Center Scientific Report 2002
TUMOR IMMUNOLOGY PROGRAM PROGRAM LEADER Diana M. Lopez, Ph.D. Professor of Microbiology and Immunology DESCRIPTION OF PROGRAM The Tumor Immunology Program presently consists of 16 faculty members from five different departments at the University of Miami School of Medicine. The program comprises multiple aspects of basic immunology and a substantial number of studies involving tumor systems and patient samples. The program investigates numerous aspects of the immune system in relation to the development and treatment of cancer. GOALS OF THE PROGRAM 1) Elucidation of the mechanisms underlying the activities of innate and adaptive immune cells. 2) Study of various aspects of stem cell biology and bone marrow transplantation. 3) Analysis of the role of T cells in the host defenses against tumors. 4) Mechanisms of tumor evasion of the immune system. 5) Devise novel immunotherapeutic protocols. PARTICIPANTS Adkins, Rebecca D., Ph.D. Microbiology and Immunology Blomberg, Bonnie B., Ph.D. Microbiology and Immunology Hnatyszyn, H. James, Ph.D. Microbiology and Immunology Jurecic, Roland, Ph.D. Microbiology and Immunology Kraus, Gunter K., Ph.D. Microbiology and Immunology Lee, Kelvin P., M.D. Microbiology and Immunology Levy, Robert B., Ph.D. Microbiology and Immunology Lichtenheld, Mathias G., M.D. Microbiology and Immunology Lopez, Diana M., Ph.D. Microbiology and Immunology Malek, Thomas R., Ph.D. Microbiology and Immunology Murray, Timothy G., M.D. Ophthalmology Podack, Eckhard R., M.D., Ph.D. Microbiology and Immunology Riley, Richard L., Ph.D. Microbiology and Immunology Rosenblatt, Joseph D., M.D. Medicine Thomas, Giovanna R., M.D. Otolaryngology Vincek, Vladimir, M.D., Ph.D. Pathology HIGHLIGHTS • Compromised humoral immune response in aged individuals may be at least partially explained by antibody V H repertoire differences at the pre-B cell level (before antigen selection). (Blomberg) • Breast cancer patients show improved immune response after psychosocial intervention. (Blomberg) • Design and developed both hammerhead ribozymes and RNAse P molecules that target and effectively cleave the 1:19 breakpoint observed in some childhood leukemias. Received funding from the Leukemia Research Foundation to evaluate this gene therapy in leukemia cell lines and primary human leukemia cell samples. (Kraus, Hnatyszyn) • Design, construction, and current evaluation of several anti-telomerase ribozymes in human cancer cell lines. (Kraus, Hnatyszyn) • Direct activation of protein kinase C causes normal human hematopoietic CD34 + stem cells to differentiate into dendritic cells. (Lee) • Protein kinase C activation causes many myeloid leukemias to differentiate into immunologically functional “leukemic” dendritic cells. These cells have potential utility as “cellular” anti-leukemia vaccines. (Lee) • T cell activation may play a critical role in the pathogenesis of opportunistic infections. (Lee) • Discovery that after allogeneic bone marrow transplant, recipient can resist the engraftment of transplanted donor stem cells by using immune responses, which do not involve the two major pathways of T lymphocyte mediated killing. This is a surprising finding and demonstrates that it is likely that for some transplants, different pathways in the recipient must be blocked to help the transplanted bone marrow engraft. (Levy) • Learned that lymphocytes, which added to donor stem cells before transplant to help or facilitate the engraftment by these stem cells after transplant, use different functions for the purposes of 1) helping to “seed” the stem cells in the recipient and 2) helping to maintain their permanent presence. (Levy) • Identified two essential enhancers of the perforin gene and demonstrated that they are under the control of Stat5 molecules. This work sheds molecular UM/Sylvester Comprehensive Cancer Center Scientific Report 2002 21
Page 1 and 2: TABLE OF CONTENTS SCIENTIFIC REPORT
Page 3 and 4: INTRODUCTION W. Jarrard Goodwin, M.
Page 5 and 6: The Tumor Cell Biology Program cont
Page 7 and 8: ership of Dr. Goodwin, and with the
Page 9 and 10: SYLVESTER COMPREHENSIVE CANCER CENT
Page 11 and 12: TUMOR CELL BIOLOGY PROGRAM PROGRAM
Page 13 and 14: Dimitropoulou, A and Bixby, JL. Reg
Page 15 and 16: ticle from ascites tumor cell micro
Page 17 and 18: PUBLICATIONS Carraway, KL III, Ross
Page 19 and 20: treated with rho 123, lactic acid a
Page 21 and 22: ments which then interact with a HA
Page 23 and 24: PUBLICATIONS Mayeda, A, Screaton, G
Page 25 and 26: PUBLICATIONS Rudd, KE. Novel interg
Page 27 and 28: PUBLICATIONS Ing, D, Zang, J, Dzau,
Page 29: PUBLICATIONS Welsh, CF, Assoian, RK
Page 33 and 34: PUBLICATIONS Adkins, B. Apoptosis o
Page 35 and 36: cDNA microarray in order to perform
Page 37 and 38: they are “doubly cytotoxic defici
Page 39 and 40: PUBLICATIONS Charyulu, VI and Lopez
Page 41 and 42: suppression of c-Myc. In addition C
Page 43 and 44: HIGHLIGHTS/DISCOVERIES • The mole
Page 45 and 46: Giovana R. Thomas, M.D. Assistant P
Page 47 and 48: VIRAL ONCOLOGY PROGRAM PROGRAM LEAD
Page 49 and 50: sensitive cell lines as well as inh
Page 51 and 52: Lawrence H. Boise, Ph.D. Assistant
Page 53 and 54: ated apoptosis in adult T-cell leuk
Page 55 and 56: CANCER PREVENTION AND CONTROL PROGR
Page 57 and 58: Michael H. Antoni, Ph.D. Professor
Page 59 and 60: women assigned to CBSM showed incre
Page 61 and 62: women, greater involvement in relig
Page 63 and 64: Adarsh M. Kumar, Ph.D. Research Ass
Page 65 and 66: CLINICAL ONCOLOGY RESEARCH PROGRAM
Page 67 and 68: PUBLICATIONS Lokeshwar, BL, Schwart
Page 69 and 70: Phase III Randomized Study of Whole
Page 71 and 72: gical resections and reconstruction
Page 73 and 74: PUBLICATIONS Johnson, BW and Boise,
Page 75 and 76: fects of stressors and stress manag
Page 77 and 78: N. Concerns about breast cancer and
Page 79 and 80: DESCRIPTION OF RESEARCH Lung Cancer
Page 81 and 82:
Clinical Oncology Research Program
Page 83 and 84:
SHARED RESOURCES DESCRIPTION Shared
Page 85 and 86:
a result, outstanding images can be
Page 87 and 88:
DIVISION OF BIOSTATISTICS DIVISION
Page 89 and 90:
DIVISION OF INFORMATICS DIVISION CH
Page 91 and 92:
SCIENTIFIC REPORT PUBLICATIONS 1999
Page 93 and 94:
Heylbroek, C, DeLuca, C, Lin, R, Ba
Page 95 and 96:
ing protein, ICP8. Journal of Biolo
Page 97 and 98:
Price-Schiavi, SA, Perez, A, Barco,
Page 99 and 100:
Fischl, MA. Antiretroviral therapy
Page 101 and 102:
cavity reconstruction. Archives of
Page 103 and 104:
Frankfurt, OS and Krishan, A. Ident
Page 105 and 106:
Lokeshwar, VB, Young, MJ, Goudarzi,
Page 107 and 108:
Schoell, WM, Mirhashemi, R, Liu, B,
Page 109 and 110:
Nakagawa, N, Parel, JM and Murray,
Page 111 and 112:
ond Edition, Granoff, A; Webster, R
Page 113 and 114:
lon mimicking a primary invasive bl
Page 115 and 116:
ducible factor-1, activator protein
show all

tumor cell biology program - Sylvester Comprehensive Cancer Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?